CyFluATG in Lower Risk MDS

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 6, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

cyclophosphamide, fludarabine, and antithymocyte globulin

"1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)"

Trial Locations (1)

05505

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER